Oncocyte (NASDAQ:IMDX) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Oncocyte (NASDAQ:IMDX) from a hold rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

IMDX has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncocyte in a research note on Monday, September 21st. Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of Oncocyte in a research report on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Oncocyte currently has an average rating of “Hold” and an average price target of $10.50.

Oncocyte Trading Up 6.7%

Shares of IMDX opened at $3.67 on Friday. Oncocyte has a 12-month low of $2.42 and a 12-month high of $8.51. The company has a market cap of $120.08 million, a PE ratio of -2.46 and a beta of 1.80. The stock has a 50-day moving average price of $4.17 and a 200-day moving average price of $4.61.

Oncocyte (NASDAQ:IMDX) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $0.24 million for the quarter.

Oncocyte Company Profile

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing tests that support cancer care. Its products are designed to help physicians assess tumor biology, estimate the risk of disease recurrence or progression, and guide treatment decisions using molecular information from patient samples.

The company’s portfolio has included tissue- and blood-based diagnostic tests for oncology applications, including assays intended to help identify patients who may benefit from particular therapies or require closer monitoring.